Skip to main content

Moderna stock forecast 2025： MRNA is worth buying for 5 reasons

MRNA

Moderna was founded in 2009 and was established in Cambridge, Massachusetts, USA. Its main business is genetic engineering and focuses on the research and development of mRNA-derived drugs.

The full name of mRNA is messenger RNA, pre-messenger RNA, a kind of immature single-stranded messenger ribonucleic acid, once it is completely processed, it is called "mature messenger RNA", or "mRNA".

These drugs use mRNA as a treatment method and use mRNA as the basis to inject the developed synthetic mRNA into the patient's body so that the patient's own cells can obtain the ability to treat themselves.

At present, the new crown vaccine being researched and developed by Moderna has an effective rate of 94.5%, so it has become one of the vaccines that are sold in large quantities all over the world.

Cambridge, Massachusetts, is not only home to Harvard University but also a world-renowned hot spot for modern biomedicine.

Despite such a "gorgeous background", Moderna's entrepreneurial road is not smooth.

Between 2010 and 2016, this company carried out a series of research and development for conventional vaccines, in an attempt to occupy this vast market and lucrative field with new vaccines.

However, these R&D and clinical trials have basically failed.

However, in this process of innovation, Modena established a leading position in the mRNA field, which attracted the attention of many pharmaceutical companies.

In 2013, Moderna entered the field of therapeutic vaccines in cooperation with AstraZeneca.

In 2014, Moderna joined forces with Alexion to enter the field of rare diseases.

Unfortunately, these cooperative studies have yet to yield results.

This makes some experts directly question the true reliability of Moderna's technology.

However, the outbreak of the new crown epidemic in 2020 gave Moderna an opportunity.

The effective rate of the new crown vaccine and the recent announcement of the clinical results of their therapeutic tumor vaccine has caused the stock price to rise sharply.

From January 1, 2020, to January 25, 2021, Moderna's stock has risen 690%.

Regarding Moderna's financial situation.

In May of this year, Moderna made a profit for the first time, with revenue of US$1.9 billion in the first quarter, and the new crown vaccine contributed nearly 90%.

Company valuation: it is still at a loss stage, and the price-earnings ratio does not exist;

P/B ratio = 23.01

Price-to-earnings ratio = price per share/earnings per share, it is one of the important indicators to measure whether a stock has investment value.

Under normal circumstances, the lower the price-earnings ratio of a stock, the lower the profitability of the market price relative to the stock, indicating that the shorter the investment payback period, the smaller the investment risk, and the greater the investment value of the stock.

If the price-to-book ratio is negative, it means that the company is still at a loss-making stage, and the risk is high, and it is impossible to predict the payback period of the investment.

PS: The price-to-book ratio refers to the ratio between the market price and the net assets per share. The price-to-book ratio = price per share/net assets per share. The lower the ratio, the lower the risk.

On January 25, 2021, the company's market value was 57.5 billion U.S. dollars, which is a company with a large market value.

Moderna is worth buying mainly for 5 reasons:

First of all, mRNA technology is extremely original, and RNA vaccines have been developed. It is the first to verify that the use of RNA can produce vaccines, and it is difficult for new competitors to replicate in a short period.

Due to the relatively high technical threshold for the development of mRNA vaccines, there is currently no product on the market for mRNA vaccines other than Pfizer, and its industry maturity needs to be improved.

The research and development principle of this type of vaccine is to deliver mRNA carrying the genetic information of the virus's characteristic protein into the cell and activate the immune response through expression in the body, thereby producing effective antibodies.

The process of human immunity with mRNA vaccine mimics the process of virus invasion to a certain extent and can stimulate human cellular and humoral immune responses.

Therefore, mRNA vaccines have multiple advantages such as strong immune activity, short research and development cycle, and suitable for the prevention of sudden infectious diseases, and are considered by the industry to have breakthrough potential.

Second, the product pipeline is rich. In addition to the new crown vaccine that is already on the market, Moderna's research and development line also have 1 phase 3 clinical, 7 phase 2 clinical trials, and 5 phase 1 clinical pharmaceuticals.

Third, the current clinical phase 2 data of the Moderna cytomegalovirus vaccine is good, and it enters clinical phase 3. If successful, it will be the only one on the market.

Fourth, before the outbreak of the new crown epidemic, Moderna's mRNA vaccine has carried out multiple clinical studies in the field of preventive vaccines and therapeutic tumor vaccines, of which the fastest progress is still in the phase II clinical trial stage.

Therefore, in addition to the vaccine field, RNA technology is also at the forefront of cancer immunotherapy, especially drugs for ovarian cancer.

Fifth, the company is currently profitable.

However, Moderna is a growth company with very high stock volatility, so we must pay attention to the investment scale during the investment process.

Labels:

Comments

Post a Comment

Popular posts from this blog

Will China's economy recover as the epidemic is under control?

During the Chinese Spring Festival, novel coronavirus broke out in Wuhan, and the Chinese stock market was hit hard. Subsequently, the Chinese government quickly took strict measures to block Wuhan, a city with a population of tens of thousands of people, to prevent the further spread of the epidemic, and to take corresponding epidemic prevention measures in other cities.  When the worst of the epidemic had already occurred, the Chinese stock market quickly rebounded. As the number of infections continues to decline, China's Shanghai Composite Index is expected to rise further. Sars Period Looking back on similar events in the past, the SARS epidemic in 2003, the stock market also made a short-term decline, and then the SARS epidemic was brought under control, the stock market immediately went up for a long time. According to past historical data, the impact of the novel coronavirus epidemic on the stock market may be short-lived. China Fund Capital Flow Howeve...
Post a Comment
Read more

The stock market entering a bear market？

On March 6, 2020, the US stock market continued its decline today after a few days of rebound. Is this the beginning of a bear market in the stock market? Next, let's analyze one important indicator of entering the bear market, Treasury bonds yield. What is the yield of Treasury bonds? Treasury bonds are a tool issued by the state to raise funds. When the bonds are issued, they promise to repay the principal and interest on a specified date. The ratio of the return of Treasury bonds to the principal invested is the return of Treasury bonds.  The main factors affecting bond yield include coupon rate, maturity, face value, holding time, purchase price, and sale price. Rising bond yields and falling bond prices mean investors are selling bonds, turning to invest activities, or entering the stock market. In a healthy economic environment, the longer the Treasury bonds, the higher the bond yield. Because short-term bonds are more liquid, investors are willing to accept lower ...
Post a Comment
Read more

How to judge the diffusive horn pattern ?

As an investment trader, you must understand the use of chart technology analysis to determine the position of market transactions. Now let's talk about a common pattern in chart technical analysis, which is the diffuse speaker pattern. Diffusion horn patterns are different from trend patterns and horizontal patterns.  Diffusion horn patterns are more difficult to judge than trend patterns and horizontal patterns, and often cause losses to investment traders. So, how do investment traders judge the spreading horn pattern and make favorable investment transactions? S&P500 Index The price trend of the diffusive horn pattern.  When the price rises over some time, then the price falls, and falls below the recent low, then rises, and rises through the last high. It keeps expanding in two directions. If we connect the high point and the low point with straight lines, respectively, we can show a horn shape, so it is called a diffuse horn shape.  Because of this, some i...
Post a Comment
Read more

The Federal Reserve implements interest rate hikes or cuts？

Generally speaking, the Federal Reserve implements interest rate hikes or cuts. Interest rate rises are austerity monetary policies, and interest rate cuts are a loose monetary policy. When the rate hike cycle begins, it indicates that the Federal Reserve is optimistic about the future economic outlook, economic data shows a positive outlook, and market sentiment is optimistic. To avoid excessive economic growth, the Federal Reserve has implemented austerity monetary policy and implemented interest rate hikes. When the interest rate cut cycle begins, it means that the Federal Reserve is bad on the future economic outlook, the economic data shows a bad trend, and the market is pessimistic. To stimulate economic growth, the Federal Reserve has implemented a loose monetary policy and implemented interest rate reductions. Correlation between the S & P 500 and Federal Reserve interest rates Historical data from the S & P 500 shows that when the rate hike cycle begins, the sto...
Post a Comment
Read more

Coinbase stock forecast 2025: it's first quarterly report

  After the trading hours on May 13 (this Thursday), Coinbase Global (COIN) will release its first quarterly report.  Take this opportunity to give us a glimpse of the prospects of the first share of cryptocurrency exchanges.  Actually, on April 6, before Coinbase went public, it had already released a forecast for the first quarter of this year. The core data are as follows:  Revenue in the first quarter was approximately US$1.8 billion, a year-on-year increase of 842%; before the net profit was between US$730 million and US$800 million, the median was US$765 million, a year-on-year increase of nearly 23 times!  Assets on the platform are 223 billion US dollars, accounting for 11.3% of the market share of encrypted assets; 56 million verified users, and 6.1 million monthly transaction users (MTU).  It is worth noting that Coinbase's net profit margin reached a terrifying 42.5% in the first quarter, and the business model of “casino” is really profitable! ...
Post a Comment
Read more